DNA vectors containing mutated HIV proviruses

Details DNA vectors containing mutated HIV proviruses DNA vectors containing mutated HIV proviruses

2006-10-17

2006-10-17

Nguyen, Dave Trong (Department: 1633)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

C514S04400A, C435S320100, C435S456000, C435S366000, C536S024100, C536S023720

Reexamination Certificate

active

07122180

ABSTRACT:
The present invention pertains to mutated, non-infectious HIV viral particles, vectors for production of such particles and vaccines employing such vectors. The non-infectious particles are obtained by introducing a number of inactivating mutations into a native viral genome. These mutations are designed so as to minimize the probability of genetic reversion to an infectious virus, while retaining the basic protein content and immunogenic properties of a wild-type virion. The altered viral genome expresses proteins that can assemble into non-infectious particles which contain immunogenic components of the virus, but which are unable to infect cells. The preferred mutations are introduced in at least one amino acid position of the nucleocapsid (NC) protein in combination with at least one other mutation in an amino acid position of the reverse transcriptase (RT) protein or the In protein. In one embodiment, the mutations to the native HIV genome may also be made in at least one amino acid position of the NC protein, at least one position in the RT protein, and at least one position in the integrase (In) protein. In another embodiment, the mutations to the native HIV genome may be introduced in clusters, where two or more mutations are made in the NC protein, the RT protein, the In protein, or any combinations thereof.

REFERENCES:
patent: 5439809 (1995-08-01), Haynes et al.
patent: 5571712 (1996-11-01), Haynes et al.
patent: 5795737 (1998-08-01), Seed et al.
patent: 5861282 (1999-01-01), Aldovini et al.
patent: 5866320 (1999-02-01), Rovinski et al.
patent: 5879925 (1999-03-01), Rovinski et al.
patent: 5889176 (1999-03-01), Rovinski et al.
patent: 5912338 (1999-06-01), Rovinski et al.
patent: 5919458 (1999-07-01), Aldovini et al.
patent: 5955342 (1999-09-01), Rovinski et al.
patent: 5985641 (1999-11-01), Haynes et al.
patent: 6025125 (2000-02-01), Rovinski et al.
patent: 6080408 (2000-06-01), Rovinski et al.
patent: 6121021 (2000-09-01), Rovinski et al.
patent: 6197755 (2001-03-01), Carrano et al.
patent: 2002/0106798 (2002-08-01), Robinson et al.
Smith, The continuing HIV vaccine saga: naked emperors alongside fairy godmothers, Medical Immunity, May 6, 2005, vol. 4, No. 6, pp. 1-5.
Levy, What can be achieved with an HIV vaccine?, The Lancet, Jan. 20, 2001, vol. 9251, No. 357, pp. 223-224).
Überla, Developing an HIV Vaccine: The Role of Efficacy Studies in Nonhuman Primates, PLoS Medicine, Apr. 2005, vol. 2, Issue 4, e119.
Amara et al, Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA.MVA Vaccine, Science, 2001, vol. 292, pp. 69-74.
Gopalkrishnan et al. Use of the human EF1-a promoter for expression can significantly increase success in establishing stable cell lines with consistent expression, 1999, NAR, vol. 27(24) pp. 4775-4782.
Andre et al, Increased Immune Response Elicited by DNA Vaccination with a Synthetic gp120 Sequence with Optimized Codon Usage, 1998, JVI, vol. 72(2) pp. 1497-1503.
Blast 2 sequence results-HIV-1 HXB2 and HIV-1 BH10, downloaded May 26, 2004.
pBK phagemid vectors, Stratagene catalog, 1995, p. 26.
Blast sequence HIV-I HXB2 and pol gene sequence, downloaded May 26, 2004.
Haynes et al, Production of Immunogenic HIV-1 Virus like Particles in Stably Engineered Monkey Cell lines, Aids Research and Human Retroviruses, 1991, vol. 7(1), pp. 17-27.
Wain-Hobson et al, Nucleotide Sequence of AIDS Virus, LAV, Cell, 1985, vol. 40 pp. 9-17.
Aldovini et al. “Mutations of RNA and Protein Sequences Involved in Human Immunodeficiency Virus Type 1 Packaging Result in Production of Noninfectious Virus,”Journal of Virology, vol. 64, No. 5, May 1990, pp. 1920-1926.
Berthoux et al. “Mutations in the N-Terminal Domain of Human Immunodeficiency Virus Type 1 Nucleocapsid Protein Affect Virion Core Structure and Proviral DNA Synthesis,”Journal of Virology, vol. 71, No. 9, Sep. 1997, pp. 6973-6981.
Campbell et al. “Self-AssemblyIn Vitroof Purified CA-NC Proteins from Rous Sarcoma Viruus and Human Immunodeficiency Virus Type 1,”Journal of Virology,vol. 69, No. 10, Oct. 1995, pp. 6487-6497.
Cranage et al. “AIDS Vaccine Developments,”Nature,vol. 355, Feb. 1992, pp. 685-686.
Dannull et al. “Specific Binding of HIV-1 Nucleocapsid Protein to PSI RNAIn VitroRequires N-Terminal Zinc Finger and Flanking Basic Amino Acid Residues,”EMBO J,vol. 13, No. 7, Apr. 1, 1994, pp. 1525-1533.
Deml et al. “Multiple Effects of Codon Usage Optimization on Expression and Immunogenicity of DNA Candidate Vaccines Encoding the Human Immunodeficiency Virus Type 1 Gag Protein,”Journal of Virology, vol. 75, No. 22, Nov. 2001, pp. 10991-11001.
Druillennec et al. “A Mimic of HIV-1 Nucleocapsid Protein Impairs Reverse Transcription and Displays Antiviral Activity,”Proc. National Academy of Science USA, vol. 96, Apr. 1999, pp. 4886-4891.
Druillennec et al. “Evidence of Interactions Between the Nucleocapsid Protein NCp7 and the Reverse Transcriptase of HIV-1,”Journal of Biological Chemistry, vol. 274, No. 16, Apr. 16, 1999, pp. 11283-11288.
Lins et al. “Molecular Dynamics Studies on the HIV-1 Integrase Catalytic Domain,”Biophysical Journal, vol. 76, Jun. 1999, pp. 2999-3011.
Osterhaus et al. “AIDS Vaccine Developments,”Nature, vol. 355, Feb. 1992, pp. 684-685.
Ottmann et al. “The Central Globular Domain of the Nucleocapsid Protein of Human Immunodeficiency Virus Type 1 Is Critical for Virion Structure and Infectivity,”Journal of Virology, vol. 69, No. 3, Mar. 1995, pp. 1778-1784.
Poon et al. “Charged Amino Acid Residues of Human Immunodeficiency Virus Type 1 Nucleocapsid p7 Protein in RNA Packaging and Infectivity,”Journal of Virology, vol. 70, No. 10, Oct. 1996, pp. 6607-6616.
Poon et al. “Nucleocapsid and Matrix Protein Contributions to Selective Human Immundeficiency Virus Type 1 Genomic RNA Packaging,”Journal of Virology, vol. 72, No. 3, Mar. 1998, pp. 1983-1993.
Robinson et al. “Neutralizing Antibody-Independent Containment of Immunodeficiency Virus Challeneges by DNA Priming and Recombinant Pox Virus Booster Immunizations,”Nature Medicine, vol. 5, No. 5, May 1999, pp. 526-534.
Rodgers et al. “The Structure of Unliganded Reverse Transcriptase from the Human Immunodeficiency Virus Type 1,”Proc. National Academy of Science USA, vol. 92, Feb. 1995, pp. 1222-1226.
Schmalzbauer et al. “Mutations of Basic Amino Acids of NCp7 of Human Immunodeficiency Virus Type 1 Affect RNA Binding in Vitro,”Journal of Virology, vol. 70, No. 2, Feb. 1996, pp. 771-777.
Schwartz et al. “Distinct Functions and Requirements for the Cys-His Boxes of the Human Immunodeficiency Virus Type 1 Nucleocapsid Protein During RNA Encapsidation and Replication,”Journal of Virology, vol. 71, No. 12, Dec. 1997, pp. 9295-9305.
Sharma et al. “AZT-Related Mutation Lys70Arg in Reverse Transcriptase of Human Immunodeficiency Virus Type 1 Confers Decrease in Susceptibility to ddATP inIn VitroRT Inhibition Assay,”Virology, vol. 223, Article No. 0488, 1996, pp. 365-369.
Tanchou et al. “Role of the N-Terminal Zinc Finger of Human Immunodeficiency Virus Type 1 Nucleocapsid Protein in Virus Strucure and Replication,”Journal of Virology, vol. 72, No. 5, May 1998, pp. 4442-4447.
Turner et al. “Structural Biology of HIV,”Journal of Molecular Biology, vol. 285, Article No. jmbi. 1998.2354, 1999, pp. 1-32.
Winters et al. “Genotypic, Phenotypic, and Modeling Studies of a Deletion in the β3-β4 Region of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Gene That Is Associated With Resistance to Nucleoside Reverse Transcriptase Inhibitors,”Journal of Virology, vol. 74, No. 22, Nov. 2000, pp. 10707-10713.
Wiskerchen et al. “Human Immunodeficiency Virus Type 1 Integrase: Effects of Mutations on Viral Ability to Integrate, Direct Viral Gene Expression from Unintegrated Viral DNA Templates, and Sustain Viral Propagation in Pr

Affiliated with

Also associated with

Rating

DNA vectors containing mutated HIV proviruses does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with DNA vectors containing mutated HIV proviruses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and DNA vectors containing mutated HIV proviruses will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3705410